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Abstract
Background: This study investigated mesencephalic dopamine depletion effects on static mechanical allodynia
(SMA) elicited by chronic constriction of the infraorbitary nerve (CCI-IoN).
Methods: Dopamine depletion (6-OHDA administration into the medial forebrain bundle) effects on CCI-IoN-
induced SMA were explored using behavioral (nocifensive behavior score upon non-noxious stimuli using von Frey
filament), pharmacological (bromocriptine injections) and immunohistochemical (PKCγ and pERK1/2) techniques.
Results: The central dopamine depletion increased significantly the SMA score. Intraperitoneal and intracisternal
injections of bromocriptine alleviated the allodynic behavior observed in both CCI-IoN and CCI-IoN + 6-OHDA
animal groups. At the cellular level, dopamine depletion induced a significant increase in PKCγ expression in the
medullary dorsal horn (MDH) in rat with CCI-IoN + 6-OHDA when compared to sham animals (CCI-IoN only).
Similarly, after static non-noxious stimuli, the expression of pain marker proteins pERK1/2 within the MDH
revealed significantly a higher number of positive cells in CCI-IoN + 6-OHDA rats when compared to the
CCI-IoN group.
Conclusion: This study demonstrates that nigrostriatal dopamine depletion exacerbates the neuropathic pain
resulting from CCI-IoN. This effect is probably due to an action through descending pain inhibitory systems
which increased pain sensitization at the MDH level. It demonstrates also an analgesic effect elicited by D2R
activation at the segmental level.
Keywords: Parkinson disease, Dopamine, Pain, Substantia nigra, Chronic constriction injury, Neuropathic pain,
Infraorbitary nerve
Background
Painful traumatic trigeminal neuropathy (PTTN) follow-
ing peripheral nerve trauma is a disabling condition clinic-
ally characterized by spontaneous and evoked pain mainly
experienced as burning and/or shooting pain [1]. It results
from dysfunctions of the somatosensory system [2] and
remains a therapeutic challenge since the current treat-
ment options are unsatisfactory [3]. The physiopathogeny
of PTTN points to both peripheral mechanisms involving
neuro-glio-immuno vascular alterations mediated by
chemokines/cytokines release and central mechanisms
involving both alterations of ascending pathways and
descending controls [4–7].
Dopamine has been proposed as playing a key role in
chronic orofacial pain [8]. Nigrostriatal dopamine depletion
is associated with increased pain sensitivity and is impli-
cated in pain in different pathologies such as Parkinson’s
disease, restless leg syndrome, fibromyalgia, burning mouth
syndrome and atypical facial pain [9–13]. Conversely, stri-
atal administration of dopamine 2 receptor (D2R) agonists
has an anti-nociceptive effect mediated by the rostro-
ventromedial medulla (RVM) [14]. Similar results showed
that striatal inhibition of nociceptive responses evoked in
the trigeminal system [15–17] and chronic oro-facial pain
conditions in humans were associated with the alteration of
the nigrostriatal dopaminergic system [9, 10]. Recent re-
ports showed that bilateral or unilateral nigrostriatal dopa-
minergic lesions induce dynamic and static mechanical
allodynia in the oro-facial region [16, 18]. Since the effects
of dopamine depletion on the development of PTTN have
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not been explored, the present study aimed at investigating
the effects of nigrostriatal lesions in animals with a periph-
eral nerve injury: chronic constriction injury of the Infra
Orbitary Nerve (chronic constriction of the infraorbitary
nerve: CCI-IoN) model [19]. This model has the advantage
of using the trigeminal nerve for pain related studies [20].
Bilateral nigrostriatal chemical lesions were performed by
stereotaxic injection of the 6-OHDA toxin into medial fore-
brain bundle (MFB) in rats with CCI-IoN. In these animals,
pain behavior (nocifensive, mechanical allodynia), expres-
sion of PKCγ [(protein involved in pain chronicity) [21, 22]]
and pERK1/2 (proteins expressed upon noxious stimuli in
the spinal/medullary dorsal horn [23, 24] were assessed
with or without dopamine receptor (DR) agonists [bromo-
criptine (D2R), SKF81297 (D1R)] treatments.
Methods
Animals
Adult male Sprague–Dawley rats (N = 112, 275-325 g)
from Charles River (L’Arbresle, France) were maintained
in a controlled environment (lights on 07:00–19:00, 22 °C)
with ad libitum access to food and water. The experi-
ments followed the ethical guidelines of the Inter-
national Association for the Study of Pain, the European
Community Council directive of 24 November 1986
(86/609/EEC) and the Animal Ethics Committee of the
University of Auvergne.
6-OHDA lesion
After anesthesia (Ketamine 60 mg/kg, xylazine, 10 mg/kg),
rats were placed in a stereotaxic frame (David Kopf Instru-
ment, CA, USA) and the MFB were injected bilaterally with
6-OHDA (0.5 μL/min) dissolved in a vehicle solution
(0.02 % ascorbate saline) at a concentration of 3 μg/μL
(Sigma-Aldrich, France) in two deposits (2.25 and 2.85 μg,
respectively) at the following coordinates: anterior (A) −4.0;
lateral (L) ± 0.8; ventral (V) -8.0; tooth bar at +3.4 and A
−4.4; L ± 1.2; V −7.8; tooth bar at −2.4 [25]. To preserve ad-
renergic neurons from 6-OHDA toxicity, animals received
desipramine (25 mg/kg, i.p., Sigma-Aldrich, France)
30 min prior to the toxin injection; sham-lesioned
rats received only the vehicle at the same coordinates.
CCI-IoN surgery
CCI-IoN was performed following an established surgi-
cal procedure [5, 19]. Briefly, animals were anesthetized
using chloral hydrate (400 mg/kg i.p.) and an incision of
approximately 1 cm long was made along the gingivo-
buccal margin, begun just proximal to the first upper
molar. About 0.5 cm of the IoN was freed of adhering
tissue and two ligatures (4–0 chromic guts) separated by
a 1–2 mm interval were tied loosely around it using 4–0
chromic gut. The sham operation was identical except
that the nerve was not ligated.
Behavioral testing and analysis
The rats were adapted to the observation field (24 × 35 ×
18 cm) and for 30 min each day for 9 days prior to the
beginning of behavioral testing. During this period, the ex-
perimenter reached into the cage to apply von Frey (2 g)
stimulus on the animals’ faces. For each behavioral testing,
the rats were placed in the observation field for a 30 min
period. Stimulation was carried out when the rat was in a
sniffing/no locomotion state: with four paws placed on the
ground, neither moving nor freezing. The stimulus was
applied every 3 min onto the vibrissal pad (IoN territory).
Each series of stimulation consisted of 5 von Frey filament
(2 g) applications every 5 s alternating on each side of the
face. This stimulus is non-noxious.
Behavioral responses were quantified by a blind-
experimenter according to the method of [19]: (1) detec-
tion, the rats turn heads toward stimulus; (2) withdrawal
reaction (the rats turn head away); (3) escape/attack, the
rats avoid further contact with the stimulus, or attack
the filament; (4) asymmetric grooming, the rats display
an uninterrupted series of at least three wash strokes di-
rected at the stimulated area. An absence of response
corresponded to a zero score. A mean score value was
then calculated for each series of stimulations. All the
rats were subjected to 13 sessions of behavioral testing
at different time points: before surgery (day 1) and after
surgery, on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12.
Immunohistochemistry
A day after behavioral experiments, rats were deeply
anesthesized with urethane (1.5 g/kg i.p), the vibrissal pads
were ipsilaterally stimulated for 2 min by a von Frey fila-
ment 2 g (60 stimuli delivered, 0.5 Hz), and three minutes
later, the rats were perfused transcardially with warm
(37 °C) heparinized saline (25 IU heparin/ml) followed by
cold (10 °C) phosphate-buffered solution (0.1 M, pH 7.6)
containing 4 % paraformaldehyde and 0.03 % picric acid.
The brains were placed in 30 % sucrose and 0.05 % so-
dium azide solution overnight at 4 °C. Brainstem coronal
sections (30 μm) were cut on a freezing microtome and
collected in 0.05 M Tris-buffered saline (TBS).
Free-floating sections were placed in 1 % normal goat
serum for 1 h before overnight incubation at room
temperature in primary antibody solutions (mouse anti-
pERK1/2 [1:1000, Cell Signaling Technologies], and rabbit
anti-PKCγ [1:4000, Sigma-Aldrich and Santa Cruz]. The
corresponding secondary antibodies (1:400 for goat anti-
mouse Cy3, 1:200 for goat anti-rabbit Cy2) were incubated
at room temperature for 3 h. All antibodies were diluted
in TBS containing 0.25 % bovine serum albumin and
0.3 % Triton X-100. The sections were finally rinsed
in TBS, mounted onto gelatin-coated slides, dehy-
drated in alcohol, cleared in xylene, and cover-slipped
with distyrene-plasticizer-xylene. The specificity of the
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immunostaining was assessed by omitting primary
antibodies, which resulted in the absence of signal.
Immunostaining was analyzed using as motorized Zeiss
Axioplan 2 microscope equipped with a Hamamatsu
C4742-95 digital camera driven by MetaMorph® 5.4 soft-
ware. In each rat, image acquisition and fluorescent signal
quantification were performed from 7 different sections,
each taken at a given rostrocaudal plane within the MDH
(from 0 to −2160 μm at 360 μm intervals). Brainstem sec-
tions were categorized according to their approximate ros-
trocaudal location from the MDH subnucleus interpolaris
junction. pERK1/2 positive cells were counted and data
were expressed as the sum of the total number of labeled
cells counted from all sections analyzed in each animal [16].
PKCγ staining was quantified as previously reported [16].
Briefly, PKCγ staining was quantified within lamina IIi and
the number of positive cells was counted in lamina III.
Tyrosine hydroxylase (TH) immunolabelling was performed
(anti-TH primary antibody; Millipore, France) as described
above. The quantification procedure of the 6-OHDA
lesion impact on the SNc was reported previously [25].
Drugs and administration
Two weeks after the 6-OHDA injection, the animals were
briefly (<3 min) anesthetized with 2 % halothane using a
mask and received for intracisternal administration bromo-
criptine (7 μg/kg dissolved in 5 μl vehicle; Sigma-Aldrich,
France) or the vehicle alone (5 μl of 0.9 % saline) according
to our previous results [25]. For i.p. injection we used
bromocriptine (1 mg/kg) and SKF81297 (3 mg/kg dissolved
in 0.9 % saline; Sigma-Aldrich, France) concentrations [25].
Following a recovery period (<2 min), the rats were placed
in the observation field for 40-min period-test by a blind-
experimenter.
Statistical analysis
The results are expressed as mean ± SD. Statistical analysis
was performed using Student’s t-test, or a one-way ana-
lysis of variance (ANOVA) followed by a post hoc Student
Newman-Keuls test or a one-way Repeated Measures
(RM) ANOVA followed by a post hoc Student-Newman-
Keuls test. The level of significance was set at P < 0.05.
Results
Dopamine depletion in the substantia nigra
As shown in our previous study [25], 6-OHDA injec-
tions resulted in a considerable decrease of TH staining
in the SNc of CCI-IoN + 6-OHDA when compared to
CCI-IoN + saline animals (Additional file 1: Figure S1A
and B). Cell count revealed a significant (p < 0.001, ***)
decrease in TH positive cells (70 % neuronal loss) in
SNc of CCI-IoN + 6-OHDA rats (Additional file 1:
Figure S1C). The impact of unilateral or bilateral depletion
mesencephalic midbrain depletion on SMA has been
studied previously [18].
Dopamine depletion increases static mechanical allodynia
(SMA) resulting from CCI-IoN
The time course of SMA appearance (Fig. 1), resulting
from the CCI-IoN, was similar to our previous report [16].
Fig. 1 Time course of static mechanical allodynia (SMA) in the ipsilateral side to the injury (CCI-IoN) of 6 animal groups (each n = 8): CCI-IoN and
its sham; 6-OHDA and its sham; and 6-OHDA + CCI-IoN and its sham. CCI-IoN animals showed a significant increase in the nocifensive score at
post-surgery week 2 when compared to CCI-IoN-sham. The SMA score reached its maximum around the 4th week post-surgery and decreased
slowly through the post-surgery observation period until week 12. SMA occurred rapidly within 3–4 days after 6-OHDA injection. This related SMA
stayed significant when compared to sham for 7 weeks after the lesion. The highest nocifensive score was observed in the 6-OHDA + CCI-IoN
group in comparison to all other groups. Despite the slight decrease observed along the 12 weeks post-surgery, the SMA score in this group
remained significantly increased compared to all other groups. Comparison between CCI-IoN + 6-OHDA and CCI-IoN and 6-OHDA.
Comparison between CCI-IoN and CCI-IoN sham. Comparison between CCI-IoN+ 6-OHDA and CCI-IoN + 6-OHDA sham. Comparison between
6-OHDA and 6-OHDA sham. The bars represent standard deviation. *P< 0.05; **P< 0.01;***p < 0,001
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Briefly, 1 week post-surgery, significant SMA score (CCI-
IoN) was obtained when compared to sham and reached
its highest score (p < 0.001, ***) 3 weeks post-surgery. This
SMA was significant during 12 weeks post-injury.
The time course of 6-OHDA induced SMA appear-
ance was similar to our previous report [7]. The SMA
appeared relatively earlier after 6-OHDA injection than
after CCI-IoN (Fig. 1) and stayed significant in compari-
son to 6-OHDA-sham during the first 6 weeks after the
6-OHDA lesion.
The CCI-IoN + 6-OHDA rats showed the highest sig-
nificant (p < 0.001, ***) SMA score within the ipsilateral
side (Fig. 1) to the CCI-IoN injury in comparison to all
other animal groups. This score was highly significant
along the experiment duration. Similar results were
obtained in the contralateral side, although with lower
scores (data not shown).
Bromocriptine administration decreases the SMA
Intraperitoneal administration of bromocriptine induced a
significant, dose dependent (0.1 mg and 1 mg/Kg) de-
crease in pain scores in CCI-IoN group when compared
to sham (Fig. 2a) and its effect lasted for 6 h. The highest
dose induced the highest score decrease, (P < 0.01, **). As
a positive control SKF8129 (DR1 agonist) was used.
Its intraperitoneal administration induced a non-significant
increase in the SMA score when compared to sham
(saline-injected).
Intracisternal administration of bromocriptine (Fig. 2b)
decreased significantly the SMA score when compared
C D
A B
CCI-IoN + 6-OHDACCI-IoN + saline
Fig. 2 Effects of intraperitoneal (ip) (a, b) and intracisternal (ic) (c, d) administration of bromocriptine, SKF81297 and vehicle on nocifensive
behaviors (SMA) in the ipsilateral side of CCI-IoN + saline (a & c) and CCI-IoN + 6-OHDA (B&D). Ip administration (a) of 1 mg/Kg of bromocriptine
induces a significant antinociceptive effect in 6-OHDA-lesioned animal (n = 8) when compared to the vehicle group n = 8). This antinociceptive
effect occurred 20 min after bromocriptine injection and lasted for up to 6 h. When administered ic (b), bromocriptine (1 μg/Kg, n = 5) decreases
significantly the SMA score in comparison to the vehicle group (n = 5). The effect of bromocriptine was observed 20 min after injection and this
effect lasted for about 15 min. No significant difference in SMA scores was observed when bromocriptine was injected intracisternally 90 min after
the ip administration of sulpiride (c). Error bars = standard deviation. *P < 0.05; **P < 0.01; ***p < 0.001. *: comparison between bromo 1 mg/kg (IP)
and vehicle. #: comparison between bromo 0.1 mg/kg (IP) and vehicle
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to sham (saline-injected). Bromocriptine effect lasted
for 20 min.
Intraperitoneal administration of bromocriptine (Fig. 2c)
induced a significant dose dependent decrease in SMA
score in CCI-IoN + 6-OHDA lesioned group compared
to that of sham. Its effect lasted for 6 h. SKF81297 ad-
ministration increased the allodynic score, although this
score was not significant when compared to sham.
Intracisternal administration of Bromocriptine (Fig. 2d)
decreased significantly the SMA score compared to
that of sham (saline-injected rats) and its effect lasted
for 30 min.
PKCγ expression in the medullary dorsal horn
The general pattern of PKCγ staining was similar in both
CCI-IoN (Fig. 3a) and CCI-IoN + 6-OHDA (Fig. 3b)
groups. PKCγ staining (Fig. 3c) was highly observed within
lamina IIi and in scattered cells within lamina III [16, 22].
PKCγ staining intensity quantification in lamina IIi (Fig. 3d)
was significantly higher in both ipsilateral (P > .001, **) and
contralateral (P > .05,*) MDH sides of CCI-IoN + 6-OHDA
when compared to CCI-IoN rats. There was no significant
PKCγ staining difference between ipsi- and contralateral
sides in lamina IIi. Cell count of PKCγ positive cells in lam-
ina III (Fig. 3e) was significantly increased in CCI-IoN + 6-
OHDA when compared to CCI-IoN groups. There was no
significant cell count difference between ipsilateral and
contralateral sides.
Increased pERK1/2 expression in the MDH by 6-OHDA
pERK1/2 staining was observed in cells located princi-
pally within superficial lamina II and I of the MDH
(Fig. 4a-c). At higher magnification the pERK1/2 labeling
was observed in cells located mostly in laminae I and IIo
(Fig. 4c). Cell count of pERK1/2 positive cells was sig-
nificantly (P < .01, **) higher in CCI-IoN + 6-OHDA
(Fig 4d) when compared to CCI-IoN injured rats in the ip-
silateral side to the injury (stimulated side). There was no
significant difference in the number of pERK1/2 cells be-
tween CCI-IoN and CCI-IoN + 6-OHDA in the contralat-
eral side. However there was a significant (P > .01, **) cell
count difference between ipsi-and contralateral sides in
both groups.
PKCγ and pERK1/2 are distinct cell subtypes
pERK1/2 (Fig. 5a) and PKCγ (Fig. 5b) double labeling
revealed no co-localization of these markers in both
CCI-IoN and CCI-IoN + 6-OHDA MDH (Fig. 5c).
A summary illustration of the present results is pre-
















Fig. 3 Expression of PKCγ in saline-CCI-IoN (a) and 6-OHDA-CCI-IoN (b) animals. Intense PKCγ labeling was observed within the MDH in lamina IIi
cells and in scattered cells of lamina III in both animal groups, but the highest staining signal was observed in the 6-OHDA- group (b). c A high
magnification showing the intense label within lamina IIi and in cells within lamina III. PKCγ staining intensity analysis (d) showed a significant
increase in 6-OHDA injected animals within lamina IIi in both ipsi (P < 0.01) and contralateral (P < 0.05) sides of the MDH. PKCγ positive cell count
within lamina III (e) showed a significant increase (P < 0.05) in cell number for 6-OHDA-CCI-IoN compared to saline-CCI-IoN animals. Scale bar
represents 100 μm in A-B and 30 μm in C
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Discussion
The main results of this study are: 1) Mesencephalic
dopamine depletion augmented significantly the pain
caused by CCI-IoN. 2) Bromocriptine administrations
(intraperitoneal and intracisternal) attenuated SMA in
both CCI-IoN and CCI-IoN + 6-OHDA animals. 3) Central
dopamine depletion increased significantly PKCγ and
pERK1/2 expressions in the MDH of CCI-IoN + 6-OHDA
when compared to CCI-IoN group.
This study shows a synergistic or additional effect of cen-
tral dopamine depletion and CCI-IoN on SMA in oro-
facial territories. The dopamine depletion increased the
SMA caused by CCI-IoN. This is in agreement with our
previous studies demonstrating the induction of dynamic
and static [16, 18] mechanical allodynia in the trigeminal
system upon midbrain dopamine depletion. Bromocriptine
attenuated CCI-IoN-related SMA in a dose dependent
manner. These results highlights an MDH local action of
bromocriptine by the activation of D2R since SKF81297
(D1R agonist) had no significant effect on pain behavior.
These data are in accordance with previous results showing
a direct inhibition of superficial spinal dorsal horn neurons
by activation of D2R [26, 27].
At the molecular level, central depletion of dopamine
increased synergistically the pre-existing expressions of
PKCγ and pERK1/2 within MDH. PKCγ is known to
be a key molecule for the onset of pain chronicity
[21]. Its expression increases after CCI-IoN confirm-
ing previous studies [22, 24, 28]. Our result suggests
that the lesion of the dopaminergic nigrostriatal sys-
tem increased the SMA by acting on PKCγ cells
through descending pain inhibitory system. PKCγ cells
are known to activate a secondary cell subtype within
MDH superficial laminae which expressed pERK1/2
[28] and the specific PKCγ inhibition decreased both
the number of pERK1/2 cells and the related neuro-
pathic pain behavior [24]. This highlights the essential
role of PKCγ cells in inducing allodynia. PKCγ cells
constitute a revolving door that induces allodynia through
peripheral (CCI-IoN) or central lesions (nigrostriatal
system). Moreover, bromocriptine administration has
been shown in the same neuropathic model to de-
crease PKCγ expression levels in the MDH [16], thus
suggesting that dopamine might act directly on PKCγ
cells either by direct inhibition or indirectly through
D2Rs present at excitatory presynaptic site at the
CCI-IoN 6-OHDA CCI-IoN + 6-OHDA
SMA ++ + +++
PKCγ ++ + +++


















Fig. 4 Expression of pERK1/2 in saline-CCI-IoN (a) and 6-OHDA-CCI-IoN animals (b-c). pERK1/2 positive cells were observed within superficial laminae
of the MDH in both groups. At high magnification the pERK1/2 positive cells were observed mostly in laminae IIo and I as delimited (yellow dots) in
the figure (c). Cell count (d) of pERK1/2 positive cells showed a significant increase (P < 0.01, **) in 6-OHDA vs saline injected animals (n = 5 each group)
in the ipsilateral MDH and a non-significant increase in the contralateral side. A significant increase in the number of pERK1/2 positive cells was
observed in the ipsilateral side of 6-OHDA injected animals compared to the contralateral side. Scale bar represents 100 μm in A-B and 40 μm in C
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level of PKCγ cells. In support of the latter, D2Rs
have been detected post-synaptically on second-order
neurons [29].
The implication of basal ganglia, in the processing of
noxious somatosensory information is well documented
[30]. Activation of the dopaminergic nigrostriatal system
leads to a general anti-nociceptive effect [31], while its
alteration enhances sensitivity to noxious stimuli [32, 33].
The anti-nociceptive dopamine effect is achieved through
D2R receptors [14, 16, 31, 33].
In agreement with these data, the use of bromocriptine
in the present study demonstrated also the involvement of
D2R receptor in the anti-nociceptive effect resulting from
both central dopamine depletion and CCI-IoN.
To date no direct nigral projections to the MDH is
documented. Therefore, the increase of SMA is probably
due to the indirect modulation of the pain descending
modulatory system through the periaqueductal grey
matter (PAG) [34]. The administration of apomorphine
(a dopamine receptor agonist) into the PAG promotes
anti-nociception [35]. GABA-ergic projections from
SNc, substantia nigra reticula, ventral tegmental area
and amygdala to the PAG have been described [36, 37].
Dopamine depletion in these structures may decrease
GABA transmission at PAG level, thereby increasing the
influence of descending facilitatory pain pathways on the
MDH through the RVM. The latter represents the final
common pain modulatory system [34]. Stimulation of
striatal D2R suppressed nociceptive neuropathic pain
through RVM modulation and activation of D2R and 5-
HT receptors at the dorsal spinal horn [14]. The meso-
limbic and meso-cortical dopamine projections can also
participate to the increase of pain caused by CCI-IoN
since 6-OHDA injection has been demonstrated to induce
dopaminergic cell degeneration in the VTA [16, 18, 33].
Alternatively the segmental action of bromocriptine
(intracisternal injection) may act via dopaminergic
descending pathway which arise from the hypothalamus
region A11 [38]. Other brain structures which receive
mesencephalic dopamine innervation could also modulate
nociception at the MDH level [39].
Our data supported the implication of the mesen-
cephalic dopamine system in the PD, orofacial (burn-
ing mouth syndrome, atypical facial pain) and other
pain-related pathologies (restless leg, fibromyalgia)
(9.10.11.12, 13). It is worth to note that in PD, patients
experimented pain during the Off-period (absence of
dopamine replacement therapy) which highlighted the
general role for dopamine in pain process. Thus central
dopamine may have a general inhibitory action on
pain directly by dopaminergic projections to descending
pain control or indirectly through dopamine projections
to target nuclei and its depletion may causes a general
pain increase.
Conclusion
In conclusion the present study demonstrated a synergic
effect of CCI-IoN and central dopamine depletion in
neuropathic pain. The nigrostriatal dopamine increased
allodynic behavior through D2R at segmental PKCγ.
D2R agonists might be used as analgesic mechanism for
trigeminal allodynia.
Additional file
Additional file 1: Figure S1. Tyrosine Hydroxylase (TH) immunostaining
in saline + CCI-IoN (A) and 6-OHDA + CCI-IoN (B) animals (n = 8) revealed
a drastic decrease in the staining intensity mainly observed in the substantia
nigra pars compacta (SNc). The cell count (C) demonstrated a significant
(p < 0.001, ***) decrease in TH positive cells in the SNc of 6-OHDA
rats when compared to shams. Scale bar = 170 μm in A-B. Error bar = standard
deviation in C. ***p< 0.001. (DOC 274 kb)
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pERK1/2 PKCγ merge
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Fig. 5 Double labeling using pERK1/2 (a) and PKCγ (b) antibodies in CCI-IoN + 6-OHDA rats. No co-localization (c) between markers was observed
in MDH cells demonstating distinct cell subtypes for these markers. The bar represents 100 μm in A-C
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